Clinical Scorecard: Efficacy and Safety Comparison of Antibacterial Treatments for Severe Infections Caused by Stenotrophomonas maltophilia: A Systematic Review and Network Meta-Analysis

At a Glance

Key Highlights

• S maltophilia is associated with severe hospital-acquired pneumonia, bloodstream infections, and catheter-related infections.

• TMP-SMX is the conventional treatment, but resistance and dose-dependent adverse events can limit its use.

• Levofloxacin was associated with significantly higher overall survival than TMP-SMX and ranked first for survival.

• Tigecycline ranked first for clinical efficacy but did not demonstrate a statistically significant survival advantage over TMP-SMX.

• Minocycline performed comparatively consistently across the evaluated outcomes.

• Safety findings associated TMP-SMX with acute kidney injury, hyperkalemia, and treatment discontinuation.

Guideline-Based Recommendations

This systematic review and network meta-analysis did not establish new treatment guidelines. The authors discussed existing guidance and proposed reconsideration of the treatment hierarchy for severe S maltophilia infections.

Diagnosis

• Included studies required laboratory-confirmed S maltophilia infection.

• Respiratory tract and bloodstream infections were the most frequently reported infection sites.

• The review did not evaluate diagnostic tests or establish new diagnostic criteria.

Management

• Existing guidance identifies TMP-SMX as the conventional treatment.

• Levofloxacin and minocycline are guideline-supported primary alternatives when TMP-SMX is contraindicated or does not produce a clinical response.

• Tigecycline is increasingly used as salvage therapy for multidrug-resistant infections in intensive care settings.

• The authors proposed prioritizing levofloxacin for reducing mortality in severe infections, guided by local susceptibility patterns and antimicrobial-stewardship principles.

Monitoring & Follow-up

• Monitor patients receiving TMP-SMX for adverse events including acute kidney injury, hyperkalemia, hypersensitivity, and other dose-dependent toxicities.

• Consider treatment tolerability because adverse events may result in discontinuation or regimen changes.

• The review did not establish specific clinical follow-up intervals.

Risks

• S maltophilia has intrinsic resistance to a broad range of antimicrobial agents, including carbapenems.

• Increasing resistance and dose-dependent toxicity may limit TMP-SMX use.

• Tigecycline’s superior clinical-response ranking did not correspond to a demonstrated survival benefit.

• Regional differences in antimicrobial susceptibility may affect treatment performance.

Patient & Prescribing Data

The analysis included 15 retrospective cohorts published from 2012 through 2026. Study populations generally consisted of older, hospitalized adults, with substantial proportions requiring intensive care or mechanical ventilation.

The analysis compared TMP-SMX, levofloxacin, minocycline, and tigecycline. It primarily evaluated monotherapy, and most studies did not report outcomes separately by infection site.

Clinical Best Practices

• Base antimicrobial selection on local susceptibility patterns whenever possible.

• Consider survival, clinical response, and treatment tolerability when evaluating available regimens.

• Monitor closely for TMP-SMX-associated renal and electrolyte adverse events.

• Interpret SUCRA rankings cautiously because the evidence came entirely from retrospective cohorts with limited direct comparisons among alternative agents.

• Support prospective head-to-head studies stratified by infection site and incorporating combination regimens.

Related Resources & Content

Comparative Efficacy and Safety of Antibacterial Regimens for Severe Stenotrophomonas maltophilia Infections: A Systematic Review and Network Meta-Analysis — Gao S, Lu Y, Qiao Q. International Journal of Infectious Diseases. 2026;171:109023. doi:10.1016/j.ijid.2026.109023.